A phase 1 study of eribulin mesylate (E7389), a novel microtubule-targeting chemotherapeutic agent, in children with refractory or recurrent solid tumors: A Children's Oncology Group Phase 1 Consortium study (ADVL1314)
Keyword(s):
Phase 1
◽
2016 ◽
Vol 34
(15_suppl)
◽
pp. 10558-10558